Search
(561) 394-0024
Contact
Media
Practice News & Culture

Dr. Alan J. Bauman and the Bauman Medical Team Have a Huge Presence at the 2023 Biohacking Conference in Orlando

Dr. Bauman and 13 members of his Bauman Medical team recently attended the 9th Annual Biohacking Conference in Orlando. Dr. Bauman gave his latest talk “BIOHACKING BALDNESS: Increase Your Hairspan and Take Your Hair to the Next Level!” where...read more


All Articles

PODCAST: Sandy K Nutrition Health & Lifestyle Queen Interviews Dr. Alan J. Bauman

Episode 180 – Why Hair Loss Happens For Men & Women & What You Can Do About It with Dr. Alan J. Bauman Dr. Bauman & Sandy cover the following in this informative interview for both men & women…...read more


In The Media

HAIR LOSS AWARENESS MONTH 2023

ADVANCEMENTS IN TREATMENTS, PRODUCTS & TECHNOLOGY TO SIGNIFICANTLY IMPROVE HAIR HEALTH & APPEARANCE PRNewswire BOCA RATON, Fla., July 27, 2023 /PRNewswire/ — While for many August marks the final stretch of summer frolicking and fun, the medical community utilizes the month as...read more


Hair Loss Causes & Diagnosis

Declare Your Independence from Hair Loss

Losing hair presents a dilemma for lots of men. Ignore what’s happening and “live with it” or flounder around for a solution and be constantly on the march to adapt to their head’s ever-shifting geography. Maybe you’ve tried some...read more


Hair Loss Causes & Diagnosis

VIDEO: What Are The Most Popular Hair Regrowth Treatments at Bauman Medical?

One of the most common questions our patients ask Dr. Bauman is: “What are your most popular treatments that you provide at Bauman Medical?” In this video, Dr. Bauman talks about the most common treatments going from least invasive to more...read more


Hair Loss Causes & Diagnosis

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12 NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral...read more


Boca Raton / New York City